;PMID: 8632299
;source_file_2663.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..219] = [t:50..219]
;2)section:[e:223..339] = [t:223..339]
;3)section:[e:343..466] = [t:343..466]
;4)sentence:[e:470..669] = [t:470..669]
;5)sentence:[e:670..829] = [t:670..829]
;6)sentence:[e:830..985] = [t:830..985]
;7)sentence:[e:986..1153] = [t:986..1153]
;8)sentence:[e:1154..1249] = [t:1154..1249]
;9)sentence:[e:1250..1441] = [t:1250..1441]
;10)sentence:[e:1442..1645] = [t:1442..1645]
;11)sentence:[e:1646..1977] = [t:1646..1977]
;12)sentence:[e:1978..2188] = [t:1978..2188]
;13)sentence:[e:2190..2339] = [t:2190..2339]
;14)sentence:[e:2340..2655] = [t:2340..2655]
;15)section:[e:2659..2677] = [t:2659..2677]
;16)section:[e:2683..2697] = [t:2683..2697]
;17)section:[e:2703..2728] = [t:2703..2728]
;18)section:[e:2732..2776] = [t:2732..2776]

;section 0 Span:0..44
;J Pharmacol Exp Ther. 1996 Feb;276(2):370-9.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..11] Pharmacol) (NNP:[12..15] Exp)
        (NNP:[16..20] Ther) (.:[20..21] .) (CD:[22..26] 1996)
        (.:[27..34] Feb;276) (-LRB-:[34..35] -LRB-) (CD:[35..36] 2)
        (-RRB-:[36..37] -RRB-) (::[37..38] :) (CD:[38..41] 370) (::[41..42] -)
        (CD:[42..44] 9.)))

;sentence 1 Span:50..219
;Triazolam biotransformation by human liver microsomes in vitro: effects of 
;metabolic inhibitors and clinical confirmation of a predicted interaction
;with  ketoconazole.
;[50..59]:substance:"Triazolam"
;[136..146]:substance:"inhibitors"
;[206..218]:substance:"ketoconazole"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[50..59] Triazolam) (NN:[60..77] biotransformation))
      (PP (IN:[78..80] by)
        (NP (JJ:[81..86] human) (NN:[87..92] liver) (NNS:[93..103] microsomes)))
      (ADVP (FW:[104..106] in) (FW:[107..112] vitro)))
    (::[112..113] :)
    (NP
      (NP
        (NP (NNS:[114..121] effects))
        (PP (IN:[122..124] of)
          (NP (JJ:[126..135] metabolic) (NNS:[136..146] inhibitors))))
      (CC:[147..150] and)
      (NP
        (NP (JJ:[151..159] clinical) (NN:[160..172] confirmation))
        (PP (IN:[173..175] of)
          (NP
            (NP (DT:[176..177] a) (VBN:[178..187] predicted)
                (NN:[188..199] interaction))
            (PP (IN:[200..204] with)
              (NP (NN:[206..218] ketoconazole)))))))
    (.:[218..219] .)))

;section 2 Span:223..339
;von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo
;MM,  Pritchard GA, Wright CE, Shader RI.
(SEC
  (FRAG (NN:[223..226] von) (NNP:[227..233] Moltke) (NNP:[234..236] LL)
        (,:[236..237] ,) (NNP:[238..248] Greenblatt) (NNP:[249..251] DJ)
        (,:[251..252] ,) (NNP:[253..260] Harmatz) (NNP:[261..263] JS)
        (,:[263..264] ,) (NNP:[265..269] Duan) (NNP:[270..272] SX)
        (,:[272..273] ,) (NNP:[274..280] Harrel) (NNP:[281..283] LM)
        (,:[283..284] ,) (NNP:[285..298] Cotreau-Bibbo) (NNP:[299..301] MM)
        (,:[301..302] ,) (NNP:[304..313] Pritchard) (NNP:[314..316] GA)
        (,:[316..317] ,) (NNP:[318..324] Wright) (NNP:[325..327] CE)
        (,:[327..328] ,) (NNP:[329..335] Shader) (NNP:[336..339] RI.)))

;section 3 Span:343..466
;Department of Pharmacology and Experimental Therapeutics, Tufts University 
;School of Medicine, Boston, Massachusetts, USA.
(SEC
  (FRAG (NNP:[343..353] Department) (IN:[354..356] of)
        (NNP:[357..369] Pharmacology) (CC:[370..373] and)
        (NNP:[374..386] Experimental) (NNP:[387..399] Therapeutics)
        (,:[399..400] ,) (NNP:[401..406] Tufts) (NNP:[407..417] University)
        (NNP:[419..425] School) (IN:[426..428] of) (NNP:[429..437] Medicine)
        (,:[437..438] ,) (NNP:[439..445] Boston) (,:[445..446] ,)
        (NNP:[447..460] Massachusetts) (,:[460..461] ,) (NNP:[462..465] USA)
        (.:[465..466] .)))

;sentence 4 Span:470..669
;Biotransformation of the triazolobenzodiazepine triazolam to its hydroxylated
; metabolites, alpha-hydroxy (OH)- and 4-OH-triazolam, was studied in vitro
;using  microsomal preparations of human liver.
;[495..527]:substance:"triazolobenzodiazepine triazolam"
;[549..560]:substance:"metabolites"
;[562..581]...[591..600]:substance:"alpha-hydroxy (OH)-"..."triazolam"
;[562..575]...[586..600]:substance:"alpha-hydroxy"..."4-OH-triazolam"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[470..487] Biotransformation))
      (PP (IN:[488..490] of)
        (NP (DT:[491..494] the)
           (NN:[495..517] triazolobenzodiazepine) (NN:[518..527] triazolam)))
      (PP (TO:[528..530] to)
        (NP
          (NP (PRP$:[531..534] its) (VBN:[535..547] hydroxylated)
              (NNS:[549..560] metabolites))
          (,:[560..561] ,)
          (NP
            (NP
              (NML (SYM:[562..567] alpha) (HYPH:[567..568] -)
                (NML
                  (NML (JJ:[568..575] hydroxy))
                  (NML (-LRB-:[576..577] -LRB-) (NN:[577..579] OH)
                       (-RRB-:[579..580] -RRB-))))
              (HYPH:[580..581] -)
              (NML-1 (-NONE-:[581..581] *P*)))
            (CC:[582..585] and)
            (NP (NN:[586..590] 4-OH) (HYPH:[590..591] -)
              (NML-1 (NN:[591..600] triazolam)))))))
    (,:[600..601] ,)
    (VP (VBD:[602..605] was)
      (VP (VBN:[606..613] studied)
        (NP-2 (-NONE-:[613..613] *))
        (ADVP (FW:[614..616] in) (FW:[617..622] vitro))
        (S-MNR
          (NP-SBJ (-NONE-:[622..622] *))
          (VP (VBG:[623..628] using)
            (NP
              (NP (JJ:[630..640] microsomal) (NNS:[641..653] preparations))
              (PP (IN:[654..656] of)
                (NP (JJ:[657..662] human) (NN:[663..668] liver))))))))
    (.:[668..669] .)))

;sentence 5 Span:670..829
;Mean values of Vmax (10.3 nM/min/mg of  protein) and Km (304 microM) for the
;4-OH pathway exceeded values for the  alpha-OH pathway (2.4 and 74,
;respectively).
;[685..689]:quantitative-name:"Vmax"
;[691..695]:quantitative-value:"10.3"
;[696..717]:quantitative-units:"nM/min/mg of  protein"
;[723..725]:quantitative-name:"Km"
;[727..730]:quantitative-value:"304"
;[731..737]:quantitative-units:"microM"
;[803..806]:quantitative-value:"2.4"
;[811..813]:quantitative-value:"74"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[670..674] Mean) (NNS:[675..681] values))
      (PP (IN:[682..684] of)
        (NP
          (NP (NN:[685..689] Vmax)
            (PRN (-LRB-:[690..691] -LRB-)
              (NP
                (NP (CD:[691..695] 10.3) (NN:[696..698] nM))
                (PP (SYM:[698..699] /)
                  (NP (NN:[699..702] min)))
                (PP (SYM:[702..703] /)
                  (NP
                    (NP (NN:[703..705] mg))
                    (PP (IN:[706..708] of)
                      (NP (NN:[710..717] protein))))))
              (-RRB-:[717..718] -RRB-)))
          (CC:[719..722] and)
          (NP (NN:[723..725] Km)
            (PRN (-LRB-:[726..727] -LRB-)
              (NP (CD:[727..730] 304) (NN:[731..737] microM))
              (-RRB-:[737..738] -RRB-)))))
      (PP (IN:[739..742] for)
        (NP (DT:[743..746] the) (NN:[747..751] 4-OH) (NN:[752..759] pathway))))
    (VP (VBD:[760..768] exceeded)
      (NP
        (NP (NNS:[769..775] values))
        (PP (IN:[776..779] for)
          (NP (DT:[780..783] the) (NN:[785..793] alpha-OH)
              (NN:[794..801] pathway)))
        (PRN (-LRB-:[802..803] -LRB-)
          (FRAG
            (NP (CD:[803..806] 2.4) (CC:[807..810] and) (CD:[811..813] 74))
            (,:[813..814] ,)
            (ADVP (RB:[815..827] respectively)))
          (-RRB-:[827..828] -RRB-))))
    (.:[828..829] .)))

;sentence 6 Span:830..985
;However the mean Vmax/Km ratios for  the two pathways were nearly identical,
;indicating that both contribute  approximately equally to intrinsic
;clearance.
;[847..854]:quantitative-name:"Vmax/Km"
(SENT
  (S
    (ADVP (RB:[830..837] However))
    (NP-SBJ
      (NP (DT:[838..841] the) (JJ:[842..846] mean)
        (NML
          (NML (NN:[847..851] Vmax))
          (PP (SYM:[851..852] /)
            (NP (NN:[852..854] Km))))
        (NNS:[855..861] ratios))
      (PP (IN:[862..865] for)
        (NP (DT:[867..870] the) (CD:[871..874] two) (NNS:[875..883] pathways))))
    (VP (VBD:[884..888] were)
      (ADJP-PRD (RB:[889..895] nearly) (JJ:[896..905] identical))
      (,:[905..906] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[906..906] *))
        (VP (VBG:[907..917] indicating)
          (SBAR (IN:[918..922] that)
            (S
              (NP-SBJ (DT:[923..927] both))
              (VP (VBP:[928..938] contribute)
                (ADVP (RB:[940..953] approximately) (RB:[954..961] equally))
                (PP-CLR (TO:[962..964] to)
                  (NP (JJ:[965..974] intrinsic) (NN:[975..984] clearance)))))))))
    (.:[984..985] .)))

;sentence 7 Span:986..1153
;Ketoconazole was a powerful  inhibitor of triazolam biotransformation, having
;mean competitive Ki values of  0.006 and 0.023 microM for the alpha-OH and
;4-OH pathways.
;[986..998]:substance:"Ketoconazole"
;[1015..1024]:substance:"inhibitor"
;[1028..1037]:substance:"triazolam"
;[1081..1083]:quantitative-name:"Ki"
;[1095..1100]:quantitative-value:"0.006"
;[1105..1110]:quantitative-value:"0.023"
;[1111..1117]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ (NN:[986..998] Ketoconazole))
    (VP (VBD:[999..1002] was)
      (NP-PRD
        (NP (DT:[1003..1004] a) (JJ:[1005..1013] powerful)
            (NN:[1015..1024] inhibitor))
        (PP (IN:[1025..1027] of)
          (NP (NN:[1028..1037] triazolam) (NN:[1038..1055] biotransformation))))
      (,:[1055..1056] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1056..1056] *))
        (VP (VBG:[1057..1063] having)
          (NP
            (NP (JJ:[1064..1068] mean) (JJ:[1069..1080] competitive)
                (NN:[1081..1083] Ki) (NNS:[1084..1090] values))
            (PP (IN:[1091..1093] of)
              (NP
                (NP (CD:[1095..1100] 0.006)
                  (NML-2 (-NONE-:[1100..1100] *P*)))
                (CC:[1101..1104] and)
                (NP (CD:[1105..1110] 0.023)
                  (NML-2 (NN:[1111..1117] microM)))))
            (PP (IN:[1118..1121] for)
              (NP (DT:[1122..1125] the)
                (NML
                  (NML (NN:[1126..1134] alpha-OH)
                    (NML-1 (-NONE-:[1134..1134] *P*)))
                  (CC:[1135..1138] and)
                  (NML (NN:[1139..1143] 4-OH)
                    (NML-1 (NNS:[1144..1152] pathways))))))))))
    (.:[1152..1153] .)))

;sentence 8 Span:1154..1249
;This is consistent  with the role of P450-3A isoforms in mediating triazolam
;biotransformation.
;[1191..1207]:cyp450:"P450-3A isoforms"
;[1221..1230]:substance:"triazolam"
(SENT
  (S
    (NP-SBJ (DT:[1154..1158] This))
    (VP (VBZ:[1159..1161] is)
      (ADJP-PRD (JJ:[1162..1172] consistent)
        (PP (IN:[1174..1178] with)
          (NP
            (NP (DT:[1179..1182] the) (NN:[1183..1187] role))
            (PP (IN:[1188..1190] of)
              (NP (NN:[1191..1198] P450-3A) (NNS:[1199..1207] isoforms)))
            (PP (IN:[1208..1210] in)
              (S-NOM
                (NP-SBJ (-NONE-:[1210..1210] *))
                (VP (VBG:[1211..1220] mediating)
                  (NP (NN:[1221..1230] triazolam)
                      (NN:[1231..1248] biotransformation)))))))))
    (.:[1248..1249] .)))

;sentence 9 Span:1250..1441
;The  serotonin2 antagonist antidepressant nefazodone inhibited the alpha-OH
;and 4-OH  pathways (Ki = 0.6 and 1.7 microM, respectively), but with
;considerably less  activity than ketoconazole.
;[1255..1265]:substance:"serotonin2"
;[1266..1291]:substance:"antagonist antidepressant"
;[1292..1302]:substance:"nefazodone"
;[1346..1348]:quantitative-name:"Ki"
;[1351..1354]:quantitative-value:"0.6"
;[1359..1362]:quantitative-value:"1.7"
;[1363..1369]:quantitative-units:"microM"
;[1428..1440]:substance:"ketoconazole"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1250..1253] The)
        (NML (NN:[1255..1265] serotonin2) (NN:[1266..1276] antagonist))
        (NN:[1277..1291] antidepressant))
      (NP (NN:[1292..1302] nefazodone)))
    (VP (VBD:[1303..1312] inhibited)
      (NP (DT:[1313..1316] the)
        (NML
          (NML (NN:[1317..1325] alpha-OH)
            (NML-2 (-NONE-:[1325..1325] *P*)))
          (CC:[1326..1329] and)
          (NML (NN:[1330..1334] 4-OH)
            (NML-2 (NNS:[1336..1344] pathways)))
          (PRN (-LRB-:[1345..1346] -LRB-)
            (PRN
              (NP-SBJ (NN:[1346..1348] Ki))
              (VP (SYM:[1349..1350] =)
                (NP
                  (NP (CD:[1351..1354] 0.6)
                    (NML-1 (-NONE-:[1354..1354] *P*)))
                  (CC:[1355..1358] and)
                  (NP (CD:[1359..1362] 1.7)
                    (NML-1 (NN:[1363..1369] microM))))
                (,:[1369..1370] ,)
                (ADVP (RB:[1371..1383] respectively))))
            (-RRB-:[1383..1384] -RRB-))))
      (,:[1384..1385] ,)
      (NAC (CC:[1386..1389] but)
        (PP (IN:[1390..1394] with)
          (NP
            (NP
              (ADJP (RB:[1395..1407] considerably) (JJR:[1408..1412] less))
              (NN:[1414..1422] activity))
            (PP (IN:[1423..1427] than)
              (NP (NN:[1428..1440] ketoconazole)))))))
    (.:[1440..1441] .)))

;sentence 10 Span:1442..1645
;Among six selective serotonin reuptake-inhibitor  antidepressants,
;norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0  microM) and
;fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).
;[1462..1507]:substance:"serotonin reuptake-inhibitor  antidepressants"
;[1509..1522]:substance:"norfluoxetine"
;[1543..1552]:substance:"inhibitor"
;[1554..1556]:quantitative-name:"Ki"
;[1559..1562]:quantitative-value:"2.7"
;[1567..1570]:quantitative-value:"8.0"
;[1572..1578]:quantitative-units:"microM"
;[1584..1594]:substance:"fluoxetine"
;[1619..1621]:quantitative-name:"Ki"
;[1624..1627]:quantitative-value:"7.0"
;[1632..1636]:quantitative-value:"44.3"
;[1637..1643]:quantitative-units:"microM"
(SENT
  (S
    (PP (IN:[1442..1447] Among)
      (NP (CD:[1448..1451] six)
        (NML (JJ:[1452..1461] selective)
          (NML (NN:[1462..1471] serotonin) (NN:[1472..1480] reuptake))
          (HYPH:[1480..1481] -) (NN:[1481..1490] inhibitor))
        (NNS:[1492..1507] antidepressants)))
    (,:[1507..1508] ,)
    (S
      (NP-SBJ (NN:[1509..1522] norfluoxetine))
      (VP (VBD:[1523..1526] was)
        (NP-PRD (DT:[1527..1530] the)
          (ADJP (RBS:[1531..1535] most) (JJ:[1536..1542] potent))
          (NN:[1543..1552] inhibitor))
        (PRN (-LRB-:[1553..1554] -LRB-)
          (S
            (NP-SBJ (NN:[1554..1556] Ki))
            (VP (SYM:[1557..1558] =)
              (NP
                (NP (CD:[1559..1562] 2.7)
                  (NML-2 (-NONE-:[1562..1562] *P*)))
                (CC:[1563..1566] and)
                (NP (CD:[1567..1570] 8.0)
                  (NML-2 (NN:[1572..1578] microM))))))
          (-RRB-:[1578..1579] -RRB-))))
    (CC:[1580..1583] and)
    (S
      (NP-SBJ
        (NP (NN:[1584..1594] fluoxetine))
        (NP (PRP:[1595..1601] itself)))
      (VP (VBD:[1602..1605] was)
        (NP-PRD (DT:[1606..1609] the) (JJS:[1610..1617] weakest)
          (PRN (-LRB-:[1618..1619] -LRB-)
            (S
              (NP-SBJ (NN:[1619..1621] Ki))
              (VP (SYM:[1622..1623] =)
                (NP
                  (NP (CD:[1624..1627] 7.0)
                    (NML-1 (-NONE-:[1627..1627] *P*)))
                  (CC:[1628..1631] and)
                  (NP (CD:[1632..1636] 44.3)
                    (NML-1 (NN:[1637..1643] microM))))))
            (-RRB-:[1643..1644] -RRB-)))))
    (.:[1644..1645] .)))

;sentence 11 Span:1646..1977
;In a  double-blind clinical pharmacokinetic-pharmacodynamic study,
;administration of  triazolam (0.125 mg) preceded by ketoconazole, compared to
;triazolam preceded by  placebo, produced a nearly 9-fold reduction in
;apparent oral clearance of  triazolam (41 vs. 337 ml/min) and a 4-fold
;prolongation of half-life (13.5 vs.  3.4 hr).
;[1732..1741]:substance:"triazolam"
;[1743..1748]:quantitative-value:"0.125"
;[1749..1751]:quantitative-units:"mg"
;[1765..1777]:substance:"ketoconazole"
;[1791..1800]:substance:"triazolam"
;[1814..1821]:substance:"placebo"
;[1841..1847]:quantitative-value:"9-fold"
;[1889..1898]:substance:"triazolam"
;[1900..1902]:quantitative-value:"41"
;[1907..1910]:quantitative-value:"337"
;[1911..1917]:quantitative-units:"ml/min"
;[1925..1931]:quantitative-value:"4-fold"
;[1959..1963]:quantitative-value:"13.5"
;[1969..1972]:quantitative-value:"3.4"
;[1973..1975]:quantitative-units:"hr"
(SENT
  (S
    (PP (IN:[1646..1648] In)
      (NP (DT:[1649..1650] a)
        (ADJP (RB:[1652..1658] double) (HYPH:[1658..1659] -)
              (JJ:[1659..1664] blind))
        (JJ:[1665..1673] clinical)
        (ADJP (JJ:[1674..1689] pharmacokinetic) (HYPH:[1689..1690] -)
              (JJ:[1690..1705] pharmacodynamic))
        (NN:[1706..1711] study)))
    (,:[1711..1712] ,)
    (NP-SBJ
      (NP
        (NP
          (NP (NN:[1713..1727] administration))
          (PP (IN:[1728..1730] of)
            (NP (NN:[1732..1741] triazolam)))
          (PRN (-LRB-:[1742..1743] -LRB-)
            (NP (CD:[1743..1748] 0.125) (NN:[1749..1751] mg))
            (-RRB-:[1751..1752] -RRB-)))
        (VP (VBN:[1753..1761] preceded)
          (NP (-NONE-:[1761..1761] *))
          (PP (IN:[1762..1764] by)
            (NP-LGS (NN:[1765..1777] ketoconazole)))))
      (,:[1777..1778] ,)
      (VP (VBN:[1779..1787] compared)
        (NP (-NONE-:[1787..1787] *))
        (PP-CLR (TO:[1788..1790] to)
          (NP
            (NP (NN:[1791..1800] triazolam))
            (VP (VBN:[1801..1809] preceded)
              (NP (-NONE-:[1809..1809] *))
              (PP (IN:[1810..1812] by)
                (NP-LGS (NN:[1814..1821] placebo))))))))
    (,:[1821..1822] ,)
    (VP (VBD:[1823..1831] produced)
      (NP
        (NP
          (NP (DT:[1832..1833] a)
            (QP (RB:[1834..1840] nearly)
               (CD:[1841..1842] 9) (HYPH:[1842..1843] -) (JJ:[1843..1847] fold))
            (NN:[1848..1857] reduction))
          (PP (IN:[1858..1860] in)
            (NP
              (NP (JJ:[1861..1869] apparent) (JJ:[1870..1874] oral)
                  (NN:[1875..1884] clearance))
              (PP (IN:[1885..1887] of)
                (NP (NN:[1889..1898] triazolam)))))
          (PRN (-LRB-:[1899..1900] -LRB-)
            (NP
              (NP
                (NP (CD:[1900..1902] 41)
                  (NML-1 (-NONE-:[1902..1902] *P*)))
                (IN:[1903..1906] vs.)
                (NP (CD:[1907..1910] 337)
                  (NML-1 (NN:[1911..1913] ml))))
              (PP (SYM:[1913..1914] /)
                (NP (NN:[1914..1917] min))))
            (-RRB-:[1917..1918] -RRB-)))
        (CC:[1919..1922] and)
        (NP
          (NP (DT:[1923..1924] a)
            (QP (CD:[1925..1926] 4) (HYPH:[1926..1927] -) (JJ:[1927..1931] fold))
            (NN:[1932..1944] prolongation))
          (PP (IN:[1945..1947] of)
            (NP (JJ:[1948..1952] half) (HYPH:[1952..1953] -)
                (NN:[1953..1957] life)))
          (PRN (-LRB-:[1958..1959] -LRB-)
            (NP
              (NP (CD:[1959..1963] 13.5)
                (NML-2 (-NONE-:[1963..1963] *P*)))
              (IN:[1964..1967] vs.)
              (NP (CD:[1969..1972] 3.4)
                (NML-2 (NN:[1973..1975] hr))))
            (-RRB-:[1975..1976] -RRB-)))))
    (.:[1976..1977] .)))

;sentence 12 Span:1978..2188
;Pharmacodynamic testing indicated enhancement of  electroencephalographic
;beta activity, and enhanced decrements in digit-symbol  substitution test
;performance, attributable to coadministration of ketoconazole.
;[2175..2187]:substance:"ketoconazole"
(SENT
  (S
    (NP-SBJ (JJ:[1978..1993] Pharmacodynamic) (NN:[1994..2001] testing))
    (VP (VBD:[2002..2011] indicated)
      (NP
        (NP
          (NP (NN:[2012..2023] enhancement))
          (PP (IN:[2024..2026] of)
            (NP (JJ:[2028..2051] electroencephalographic)
                (SYM:[2052..2056] beta) (NN:[2057..2065] activity))))
        (,:[2065..2066] ,) (CC:[2067..2070] and)
        (NP
          (NP (VBD:[2071..2079] enhanced) (NNS:[2080..2090] decrements))
          (PP (IN:[2091..2093] in)
            (NP
              (NP
                (NML
                  (NML (NN:[2094..2099] digit) (HYPH:[2099..2100] -)
                       (NN:[2100..2106] symbol))
                  (NN:[2108..2120] substitution) (NN:[2121..2125] test))
                (NN:[2126..2137] performance))
              (,:[2137..2138] ,)
              (ADJP (JJ:[2139..2151] attributable)
                (PP (TO:[2152..2154] to)
                  (NP
                    (NP (NN:[2155..2171] coadministration))
                    (PP (IN:[2172..2174] of)
                      (NP (NN:[2175..2187] ketoconazole)))))))))))
    (.:[2187..2188] .)))

;sentence 13 Span:2190..2339
;Plasma ketoconazole concentrations measured in the clinical study ranged from
; 0.02 microgram/ml (projected minimum) to 4.95 micrograms/ml (maximum).
;[2197..2209]:substance:"ketoconazole"
;[2269..2273]:quantitative-value:"0.02"
;[2274..2286]:quantitative-units:"microgram/ml"
;[2310..2314]:quantitative-value:"4.95"
;[2315..2328]:quantitative-units:"micrograms/ml"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[2190..2196] Plasma) (NN:[2197..2209] ketoconazole)
          (NNS:[2210..2224] concentrations))
      (VP (VBN:[2225..2233] measured)
        (NP (-NONE-:[2233..2233] *))
        (PP (IN:[2234..2236] in)
          (NP (DT:[2237..2240] the) (JJ:[2241..2249] clinical)
              (NN:[2250..2255] study)))))
    (VP (VBD:[2256..2262] ranged)
      (PP
        (PP (IN:[2263..2267] from)
          (NP
            (NP (CD:[2269..2273] 0.02) (NN:[2274..2283] microgram))
            (PP (SYM:[2283..2284] /)
              (NP (NN:[2284..2286] ml)))
            (PRN (-LRB-:[2287..2288] -LRB-)
              (NP (VBN:[2288..2297] projected) (NN:[2298..2305] minimum))
              (-RRB-:[2305..2306] -RRB-))))
        (PP (TO:[2307..2309] to)
          (NP
            (NP (CD:[2310..2314] 4.95) (NNS:[2315..2325] micrograms))
            (PP (SYM:[2325..2326] /)
              (NP (NN:[2326..2328] ml)))
            (PRN (-LRB-:[2329..2330] -LRB-)
              (NP (NN:[2330..2337] maximum))
              (-RRB-:[2337..2338] -RRB-))))))
    (.:[2338..2339] .)))

;sentence 14 Span:2340..2655
;An in  vitro-in vivo scaling model, using these plasma ketoconazole
;concentrations  together with liver partition ratios and the in vitro Ki
;values, predicted a  decrement of triazolam clearance due to ketoconazole
;coadministration that was  consistent with the 88% decrement in clearance
;actually observed in vivo.
;[2395..2407]:substance:"ketoconazole"
;[2478..2480]:quantitative-name:"Ki"
;[2515..2524]:substance:"triazolam"
;[2542..2554]:substance:"ketoconazole"
;[2602..2605]:quantitative-value:"88%"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2340..2342] An)
        (ADJP
          (ADJP (FW:[2343..2345] in) (FW:[2347..2352] vitro))
          (HYPH:[2352..2353] -)
          (ADJP (FW:[2353..2355] in) (FW:[2356..2360] vivo)))
        (VBG:[2361..2368] scaling) (NN:[2369..2374] model))
      (,:[2374..2375] ,)
      (VP (VBG:[2376..2381] using)
        (NP
          (NP (DT:[2382..2387] these) (NN:[2388..2394] plasma)
              (NN:[2395..2407] ketoconazole) (NNS:[2408..2422] concentrations))
          (PP
            (ADVP (RB:[2424..2432] together))
            (IN:[2433..2437] with)
            (NP
              (NP (NN:[2438..2443] liver) (NN:[2444..2453] partition)
                  (NNS:[2454..2460] ratios))
              (CC:[2461..2464] and)
              (NP (DT:[2465..2468] the)
                (ADJP (FW:[2469..2471] in) (FW:[2472..2477] vitro))
                (NN:[2478..2480] Ki) (NNS:[2481..2487] values)))))))
    (,:[2487..2488] ,)
    (VP (VBD:[2489..2498] predicted)
      (NP
        (NP
          (NP (DT:[2499..2500] a) (NN:[2502..2511] decrement))
          (PP (IN:[2512..2514] of)
            (NP (NN:[2515..2524] triazolam) (NN:[2525..2534] clearance)))
          (PP (IN:[2535..2538] due)
            (PP (TO:[2539..2541] to)
              (NP (NN:[2542..2554] ketoconazole)
                  (NN:[2555..2571] coadministration)))))
        (SBAR
          (WHNP-1 (WDT:[2572..2576] that))
          (S
            (NP-SBJ-1 (-NONE-:[2576..2576] *T*))
            (VP (VBD:[2577..2580] was)
              (ADJP-PRD (JJ:[2582..2592] consistent)
                (PP (IN:[2593..2597] with)
                  (NP
                    (NP
                      (NP (DT:[2598..2601] the)
                        (NML (CD:[2602..2604] 88) (NN:[2604..2605] %))
                        (NN:[2606..2615] decrement))
                      (PP (IN:[2616..2618] in)
                        (NP (NN:[2619..2628] clearance))))
                    (VP
                      (ADVP (RB:[2629..2637] actually))
                      (VBN:[2638..2646] observed)
                      (NP (-NONE-:[2646..2646] *))
                      (ADVP (FW:[2647..2649] in) (FW:[2650..2654] vivo)))))))))))
    (.:[2654..2655] .)))

;section 15 Span:2659..2677
;Publication Types:
(SEC
  (FRAG (NNP:[2659..2670] Publication) (NNP:[2671..2676] Types)
        (::[2676..2677] :)))

;section 16 Span:2683..2697
;Clinical Trial
(SEC
  (FRAG (NNP:[2683..2691] Clinical) (NNP:[2692..2697] Trial)))

;section 17 Span:2703..2728
;Controlled Clinical Trial
(SEC
  (FRAG (NNP:[2703..2713] Controlled) (NNP:[2714..2722] Clinical)
        (NNP:[2723..2728] Trial)))

;section 18 Span:2732..2776
;PMID: 8632299 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2732..2736] PMID) (::[2736..2737] :) (CD:[2738..2745] 8632299)
        (NN:[2746..2747] -LSB-) (NNP:[2747..2753] PubMed) (::[2754..2755] -)
        (NN:[2756..2763] indexed) (IN:[2764..2767] for)
        (NNP:[2768..2776] MEDLINE-RSB-)))
